Studying a new drug combo for Ph+ B-ALL
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (venetoclax, olverembatinib, and prednisone) for adults newly diagnosed with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia (Ph+ B-ALL). The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been newly diagnosed with Ph+ B-ALL (a type of leukemia with a specific chromosome change).
- You should be in generally good health, able to care for yourself (ECOG score 0-2).
- Your major organs (heart, liver, kidneys, lungs) must be working well enough, with no serious uncontrolled medical conditions.
- You must agree to use effective birth control during treatment and for 12 months after the last dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a sequence of three drugs for adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL) that does not have the Philadelphia chromosome. The goal is to see if this approach can better treat the leukemia.
This Phase 2 trial tests olverembatinib plus blinatumomab for Philadelphia chromosome–positive (Ph+) ALL that is newly diagnosed. It aims to see how well this combination works and how safe it is for people who have not yet had standard leukemia medicines.
This trial tests a combination of three targeted drugs (olverembatinib, venetoclax, and dexamethasone) for people newly diagnosed with a specific type of leukemia called Ph+ ALL. The goal is to see if this combination can help control the disease without needing traditional chemotherapy.
This Phase 2 trial tests whether adding venetoclax to a chemotherapy plan works better for Philadelphia chromosome–negative acute lymphoblastic leukemia (ALL). It may help people achieve deeper remission by targeting leukemia cells in a different way than chemotherapy alone.
This trial tests a new treatment plan for children and teens newly diagnosed with a specific type of leukemia called Philadelphia chromosome-positive B-ALL. The goal is to see if the approach improves outcomes.
This trial tests a combination of three drugs—olverembatinib, a bispecific T-cell engager, and chidamide—for adults newly diagnosed with Ph+ ALL who cannot have a stem cell transplant. The goal is to see if this treatment works well without needing intensive chemotherapy.
Hear when a new Precursor B-Cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.